RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
Clinical trials for RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) explained in plain language.
Never miss a new study
Get alerted when new RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) trials appear
Sign up with your email to follow new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New MS drug candidate aims to match leading therapy in major trial
Disease control Recruiting nowThis study tests whether a new drug called ABP 692 works as well as the approved drug Ocrevus for people with relapsing-remitting multiple sclerosis (RRMS). About 444 adults with RRMS will receive either ABP 692 or Ocrevus to compare how the drugs move through the body, reduce ne…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated May 26, 2026 02:59 UTC
-
Could a gut bacteria byproduct shield MS patients from relapses?
Disease control Recruiting nowThis study tests whether a daily supplement of indole-3-propionic acid (IPA), a natural substance made by gut bacteria, can help people with relapsing-remitting multiple sclerosis (RRMS). Researchers will track 220 adults over 27 months to see if IPA reduces relapses, brain lesio…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
Phase: NA • Sponsor: Glostrup University Hospital, Copenhagen • Aim: Disease control
Last updated May 26, 2026 02:54 UTC
-
New MS drug trial aims to quiet brain lesions
Disease control Recruiting nowThis study tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). The goal is to see if it reduces brain lesions and relapses better than an existing drug. About 292 adults aged 18-55 with RRMS will take part. The trial is currently rec…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
Phase: PHASE3 • Sponsor: Biocad • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Eye-Tracking tech could revolutionize MS monitoring
Knowledge-focused Recruiting nowThis study looks at whether tracking eye movements can help doctors see how well multiple sclerosis (MS) treatment is working. About 224 Canadian adults with relapsing-remitting MS who are starting the drug ofatumumab will have their eye movements measured over time. The goal is …
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC